Kieffer Tara Lynn

SEC source: 0002064832-26-000012 · form4.xml · nonDerivative · entry 3

Kieffer Tara Lynn · CIK 0001834835 · Chief Product Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,925

F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

SEC source: 0002064832-26-000012 · form4.xml · nonDerivative · entry 2

Kieffer Tara Lynn · CIK 0001834835 · Chief Product Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,182

F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026.

SEC source: 0002064832-26-000012 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Chief Product Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,195

F1 · shares: Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026.

SEC source: 0002064832-25-000061 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Chief Product Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,620

F1 · shares: Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC source: 0002064832-25-000046 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Chief Product Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,726

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021.

SEC source: 0002064832-25-000032 · form4.xml · derivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Chief Product Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2035-11-25

F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025).

SEC source: 0001062993-25-002563 · form4.xml · nonDerivative · entry 2

Kieffer Tara Lynn · CIK 0001834835 · Chief Product Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,479

F2 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards.

SEC source: 0001062993-25-002563 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Chief Product Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,805

F1 · shares: Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025.

SEC source: 0001062993-24-020386 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Chief Product Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,305

F1 · shares: Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $7.87 to $8.22, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4.

SEC source: 0001062993-24-019987 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Chief Product Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,588

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021.

SEC source: 0001062993-24-019772 · form4.xml · derivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Chief Product Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,000

Underlying: Common Stock · 81,000 shares

Expires 2034-11-27

F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024).

SEC source: 0001062993-24-012734 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Chief Product Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,341

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2024.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.20 to $12.54, inclusive.

SEC source: 0001062993-24-003235 · form4.xml · nonDerivative · entry 2

Kieffer Tara Lynn · CIK 0001834835 · Chief Product Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,607

F2 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU awards.

SEC source: 0001062993-24-003235 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Chief Product Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,580

F1 · shares: Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2022-2023 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2024.

SEC source: 0001062993-23-022055 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Sr. VP, New Prod. Strat. & Dev

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,260

F1 · shares: Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.48 to $9.63, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4.

SEC source: 0001062993-23-021989 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Sr. VP, New Prod. Strat. & Dev

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,385

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021.

SEC source: 0001062993-23-021384 · form4.xml · derivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Sr. VP, New Prod. Strat. & Dev

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,000

Underlying: Common Stock · 83,000 shares

Expires 2033-11-22

F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 22, 2023).

SEC source: 0001062993-23-003719 · form4.xml · nonDerivative · entry 3

Kieffer Tara Lynn · CIK 0001834835 · Sr. VP, New Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,138

F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

SEC source: 0001062993-23-003719 · form4.xml · nonDerivative · entry 2

Kieffer Tara Lynn · CIK 0001834835 · Sr. VP, New Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,863

F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 18, 2020 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 13, 2023.

SEC source: 0001062993-23-003719 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Sr. VP, New Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,116

F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 18, 2020 that vested as a result of the achievement of a research and development milestone in calendar 2022 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 13, 2023.

SEC source: 0001062993-22-023367 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Sr. VP, New Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,866

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021.

SEC source: 0001062993-22-022859 · form4.xml · derivative · entry 2

Kieffer Tara Lynn · CIK 0001834835 · Sr. VP, New Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-11-23

F2 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 23, 2022).

SEC source: 0001062993-22-022859 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Sr. VP, New Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,364

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs will vest and settle with respect to 25% of the award on December 4, 2023 and in substantially equal annual installments over the next three anniversaries thereafter.

SEC source: 0001062993-22-004520 · form4.xml · nonDerivative · entry 3

Kieffer Tara Lynn · CIK 0001834835 · Sr. VP, New Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,864

F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

SEC source: 0001062993-22-004520 · form4.xml · nonDerivative · entry 2

Kieffer Tara Lynn · CIK 0001834835 · Sr. VP, New Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,416

F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 20, 2019 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 14, 2022.

SEC source: 0001062993-22-004520 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Sr. VP, New Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,127

F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 20, 2019 that vested as a result of the achievement of a research and development milestone in calendar 2021 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 14, 2022.

SEC source: 0001062993-21-011516 · form4.xml · derivative · entry 2

Kieffer Tara Lynn · CIK 0001834835 · Sr. VP, New Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,400

Underlying: Common Stock · 28,400 shares

Expires 2031-11-19

F2 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021).

SEC source: 0001062993-21-011516 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Sr. VP, New Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,800

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 19, 2021). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements.

SEC source: 0001177648-20-000049 · edgar.xml · derivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Sr. VP, New Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2030-12-07

F1 · derivative.exercise_date: Twenty-five percent (25%) of such option will become exercisable on December 7, 2021 (the "Anniversary Date"), with the remainder to become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years from the Anniversary Date (in each case subject to the optionholder's continued employment).